Gene Therapy Delivers Immune Signals Directly Into Brain Tumors in First Human Trial
A phase 1 trial shows Temferon — a gene-engineered stem cell therapy — safely delivers interferon-α into glioblastoma tumors with no dose-limiting toxicities.
Summary
Glioblastoma is one of the deadliest brain cancers, partly because it suppresses the immune system locally, preventing effective anti-tumor responses. Researchers tested Temferon, a novel therapy using a patient's own genetically engineered stem cells programmed to migrate into the tumor and release interferon-α, a potent immune-activating protein. In 24 newly diagnosed patients, the treatment was safe across all tested doses, with no dose-limiting toxicities. Median overall survival reached 16.7 months, and engineered cells persisted long-term in the blood and bone marrow. While not yet proven effective beyond standard care, the approach represents a promising strategy to deliver immune therapy precisely where it's needed inside a notoriously difficult-to-treat tumor.
Detailed Summary
Glioblastoma (GBM) remains one of the most challenging cancers to treat, with median survival under 15 months despite surgery, radiation, and chemotherapy. A key reason is its immunologically 'cold' microenvironment — dominated by immune-suppressing myeloid cells that block anti-tumor responses. Delivering immunotherapy effectively to the brain tumor site without systemic toxicity has been a major hurdle.
Researchers from IRCCS San Raffaele and collaborating Italian institutions developed Temferon, an autologous hematopoietic stem cell-based gene therapy. The approach collects a patient's own CD34+ stem cells, engineers them to produce interferon-α2 specifically when their myeloid progeny infiltrate the GBM tumor microenvironment (TME), and then reinfuses them after conditioning chemotherapy. This design aims to activate local anti-tumor immunity precisely where it is needed.
This phase 1/2a dose-escalation interim analysis treated 24 newly diagnosed GBM patients with unmethylated MGMT promoter — a group with particularly poor prognosis — across eight cohorts after surgery and radiotherapy. Doses of CD34+ cells ranged from 0.5 to 4.0 million per kilogram. No dose-limiting toxicities were observed at any dose. Adverse events were consistent with autologous stem cell transplant, including cytopenias and infections. Busulfan conditioning was selected as preferred over BCNU regimens.
Median overall survival was 16.7 months and progression-free survival was 8.1 months from diagnosis. Engineered cells were detected long-term in bone marrow and peripheral blood, confirming durable engraftment, with low but measurable systemic interferon-α levels.
While survival results appear modestly encouraging for this high-risk population, definitive efficacy conclusions require the ongoing phase 2a portion. Key caveats include the small sample size, absence of a concurrent control arm, and potential conflicts of interest among authors with financial ties to Genenta Science, the company developing Temferon.
Key Findings
- Temferon showed no dose-limiting toxicities across all 8 dose cohorts in 24 GBM patients.
- Median overall survival was 16.7 months in a typically poor-prognosis, MGMT-unmethylated GBM population.
- Engineered stem cells engrafted durably in bone marrow and blood, confirming long-term persistence.
- Busulfan conditioning was selected as the preferred regimen for further phase 2a development.
- Minimal systemic interferon-α was detected, suggesting tumor-targeted delivery with limited off-target exposure.
Methodology
Phase 1/2a dose-escalation trial enrolling 24 newly diagnosed GBM patients with unmethylated MGMT promoter across eight cohorts following surgery and radiotherapy. Temferon was administered as an autologous CD34+ stem cell transplant at doses of 0.5–4.0 × 10⁶ cells/kg, with BCNU or busulfan conditioning. Primary endpoint was safety and tolerability within 90 days; secondary endpoints included engraftment, survival, and quality of life.
Study Limitations
This interim analysis is based on the abstract only; full data, patient-level details, and biomarker analyses were not available for review. The trial lacks a concurrent randomized control arm, making survival comparisons to historical benchmarks uncertain. Several senior authors have financial conflicts of interest as cofounders or employees of Genenta Science, the commercial developer of Temferon.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.